Skip to main content
Clinical and Translational Medicine
Fig. 5 | Clinical and Translational Medicine

Fig. 5

From: Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review

Fig. 5

Disease evaluation during the treatment of crizotinib and ceritinib. a–h The CT scan revealed complete remission of lung lesions. i A single liver nodule was found after the 6 months of starting crizotinib. j The enlarged liver lesions was revealed on 20 Aug. 2014. k The liver metastasis shrinked after the treatment of ceritinib. l The liver lesions enlarged again after the 5 months of starting ceritinib

Back to article page